Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model

References

• Rehman H, Liu Q, Krishnasamy Y, et al. The mitochondria-targeted antioxidant mito Q attenuates liver fibrosis in mice. Int J Physiol Pathophysiol Pharmacol. 2016;8:14–27.
   PubMedGoogle Scholar
• Yorek MA. The role of oxidative stress in diabetic vascular and neural disease. Free Radic Res. 2003;37(5):471–480.
   PubMed Web of Science ®Google Scholar
• Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal. 2010;12(4):537–577.
   PubMed Web of Science ®Google Scholar
• Oyenihi AB, Ayeleso AO, Mukwevho E, et al. Antioxidant strategies in the management of diabetic neuropathy. Biomed Res Int. 2015;2015:1–15.
   Web of Science ®Google Scholar
• Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14(8):473.
   PubMed Web of Science ®Google Scholar
• Fernyhough P. Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Curr Diab Rep. 2015;15(11):89.
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Ang L, Holmes C, et al. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016;16(3):29.
   PubMed Web of Science ®Google Scholar
• Sifuentes-Franco S, Pacheco-Moises FP, Rodriguez-Carrizalez AD, et al. The role of oxidative stress, mitochondrial function, and autophagy in diabetic polyneuropathy. J Diabetes Res. 2017;2017:1–15.
   Google Scholar
• de Mello AH, Costa AB, Engel JDG, et al. Mitochondrial dysfunction in obesity. Life Sci. 2018;192:26–32.
   PubMed Web of Science ®Google Scholar
• Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies. Trends Endocrinol Metab. 2017;28(4):250–260.
   PubMed Web of Science ®Google Scholar
• Obrosov A, Shevalye H, Coppey LJ, et al. Effect of tempol on peripheral neuropathy in diet-induced obese and high-fat fed/low-dose streptozotocin-treated C57Bl6/J mice. Free Radic Res. 2017;51(4):360–367.
   PubMed Web of Science ®Google Scholar
• Coppey LJ, Gellett JS, Davidson EP, et al. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes. 2001;50(8):1927–1937.
   PubMed Web of Science ®Google Scholar
• Davidson EP, Coppey LJ, Shevalye H, et al. Impaired corneal sensation and nerve loss in a type 2 rat model of chronic diabetes is reversible with combination therapy of menhaden oil, α-lipoic acid, and enalapril. Cornea. 2017;36:725–731.
   PubMed Web of Science ®Google Scholar
• Davidson EP, Holmes A, Coppey LJ, et al. Effect of combination therapy consisting of enalapril, α-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat. Eur J Pharmacol. 2015;765:258–267.
   PubMed Web of Science ®Google Scholar
• Coppey LJ, Gellett JS, Davidson EP, et al. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol. 2001;134(1):21–29.
   PubMed Web of Science ®Google Scholar
• Fink BD, Herlein JA, Yorek MA, et al. Bioenergetic effects of mitochondrial-targeted coenzyme Q analogs in endothelial cells. J Pharmacol Exp Ther. 2012;342(3):709–719.
   PubMed Web of Science ®Google Scholar
• Feniouk BA, Skulachev VP. Cellular and molecular mechanisms of action of mitochondria-targeted antioxidants. Curr Aging Sci. 2017;10(1):41–48.
   PubMedGoogle Scholar
• Fink BD, Herlein JA, Guo DF, et al. A mitochondrial-targeted coenzyme Q analog prevents weight gain and ameliorates hepatic dysfunction in high-fat–fed mice. J Pharmacol Exp Ther. 2014;351(3):699–708.
   PubMed Web of Science ®Google Scholar
• Gioscia-Ryan RA, Battson ML, Cuevas LM, et al. Mitochondria-targeted antioxidant therapy with MitoQ ameliorates aortic stiffening in old mice. J Appl Physiol. 2018;124(5):1194–1202.
   PubMed Web of Science ®Google Scholar
• Miquel E, Cassina A, Martinez-Palma L, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204–213.
   PubMed Web of Science ®Google Scholar
• Rao VA, Klein SR, Bonar SJ, et al. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem. 2010;285(45):34447–34459.
   PubMed Web of Science ®Google Scholar
• Imai Y, Fink BD, Promes JA, et al. Effect of a mitochondrial-targeted coenzyme Q analog on pancreatic β-cell function and energetics in high fat fed obese mice. Pharmacol Res Perspect. 2018;6(3):e00393.
   PubMed Web of Science ®Google Scholar
• Davidson EP, Coppey LJ, Holmes A, et al. Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications. Eur J Pharmacol. 2011;668(3):497–506.
   PubMed Web of Science ®Google Scholar
• Fouret G, Tolika E, Lecomte J, et al. The mitochondrial-targeted antioxidant, MitoQ increases liver mitochondrial cardiolipin content in obesogenic diet-fed rats. Biochim Biophys Acta. 2015;1847(10):1025–1035.
   PubMed Web of Science ®Google Scholar
• Davidson EP, Coppey LJ, Kardon RH, et al. Differences and similarities in development of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic rats. Invest Ophthalmol Vis Sci. 2014;55(3):1222–1230.
   PubMed Web of Science ®Google Scholar
• Tavakoli M, Petropoulos IN, Malik RA. Assessing corneal nerve structure and function in diabetic neuropathy. Clin Exp Optom. 2012;95(3):338–347.
   PubMed Web of Science ®Google Scholar
• Coppey LJ, Davidson EP, Dunlap JA, et al. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res. 2000;1(2):131–143.
   PubMedGoogle Scholar
• Davidson EP, Coppey LJ, Calcutt NA, et al. Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev. 2010;26(4):306–318.
   PubMed Web of Science ®Google Scholar
• Yorek MA, Coppey LJ, Gellett JS, et al. Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function. Am J Physiol Endocrinol Metab. 2002;283(5):E1067–E1075.
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Drel VR, Oltman CL, et al. Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. Am J Physiol Endocrinol Metab. 2007;293(6):E1645–E1655.
   PubMed Web of Science ®Google Scholar
• Coleman MD, Eason RC, Bailey CJ. The therapeutic use of lipoic acid in diabetes: a current perspective. Environ Toxicol Pharmacol. 2001;10(4):167–172.
   PubMed Web of Science ®Google Scholar
• Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17(10):888–895.
   PubMed Web of Science ®Google Scholar
• Dincer Y, Telci A, Kayali R, et al. Effect of α-lipoic acid on lipid peroxidation and anti-oxidant enzyme activities in diabetic rats. Clin Exp Pharmacol Physiol. 2002;29(4):281–284.
   PubMed Web of Science ®Google Scholar
• Jones W, Li X, Qu ZC, et al. Uptake, recycling, and antioxidant actions of α-lipoic acid in endothelial cells. Free Radic Biol Med. 2002;33(1):83–93.
   PubMed Web of Science ®Google Scholar
• Haramaki N, Han D, Handelman GJ, et al. Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of alpha-lipoic acid. Free Radic Biol Med. 1997;22(3):535–542.
   PubMed Web of Science ®Google Scholar
• Bravenboer B, Kappelle AC, Hamers FPT, et al. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin-induced diabetic rat. Diabetologia. 1992;35(9):813–817.
   PubMed Web of Science ®Google Scholar
• van Dam PS. Oxidative stress and diabetic neuropathy: Pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2002;18(3):176–184.
   PubMed Web of Science ®Google Scholar
• Oltman CL, Davidson EP, Coppey LJ, et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab. 2008;10:64–74.
   PubMed Web of Science ®Google Scholar
• Yorek MA, Coppey LJ, Gellett JS, et al. Effect of fidarestat and α-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction. Exp Diabesity Res. 2004;5(2):123–135.
   PubMedGoogle Scholar
• Coppey LJ, Gellett JS, Davidson EP, et al. Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res. 2003;37(1):33–40.
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. What is oxidative stress? Metabolism. 2000;49(2):3–8.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Miao LF, Qian LL, et al. Molecular mechanisms of glucose fluctuations on diabetic complications. Front Endocrinol (Lausanne). 2019;10:640.
   PubMed Web of Science ®Google Scholar
• Fang F, Wang J, Wang YF, et al. Microangiopathy in diabetic polyneuropathy revisited. Euro Rev Med Pharmacol Sci. 2018;22:6456–6462.
   PubMed Web of Science ®Google Scholar
• Kennedy JM, Zochodne DW. Influence of experimental diabetes on the microcirculation of injured peripheral nerve. Diabetes. 2002;51(7):2233–2240.
   PubMed Web of Science ®Google Scholar
• Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120(1):1–34.
   PubMed Web of Science ®Google Scholar
• Dewanjee S, Das S, Das AK, et al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Euro J Pharmacol. 2018;833:472–523.
   PubMed Web of Science ®Google Scholar